Hypothesis

Cyclical AMPK activation, particularly through γ2‑containing complexes, regulates longevity by phosphorylating the nucleoporin NUP50 to create a transient “import gate” that selectively enhances nuclear import of metabolic transcription factors (FOXO3, PPARγ, PGC‑1α) while restricting pro‑growth signals (mTORC2‑AKT, SREBP). This nucleocytoplasmic gating couples cellular energy pulses to gene‑expression programs that drive autophagy, mitochondrial biogenesis, and lipid catabolism in a tissue‑specific manner, explaining why pulsed AMPK signaling yields healthspan benefits whereas chronic activation leads to adaptation resistance or deleterious effects.

Mechanistic rationale

1. AMPK‑γ2 selectivity – γ2 subunits confer heightened sensitivity to AMP/ADP and slower Thr172 dephosphorylation, producing sharper, longer‑lasting AMPK pulses after each fasting‑refeeding cycle 5. In tissues where γ2‑AMPK predominates (e.g., cardiac myocytes, hepatocytes), these pulses generate robust NUP50 phosphorylation.
2. NUP50 as a phospho‑switch – AMPK directly phosphorylates NUP50 on serine residues within its FG‑repeat domain, increasing its affinity for importin‑β1 and reducing binding to exportin‑1 (CRM1) 2. This shifts the nucleocytoplasmic equilibrium toward accumulation of cargoes bearing classical NLS motifs.
3. Cargo specificity – Phospho‑NUP50 preferentially imports transcription factors that drive catabolic programs (FOXO3, PPARγ, PGC‑1α) while sterically hindering import of mTORC2‑AKT and SREBP complexes, thereby reinforcing the AMPK‑mTORC1 antagonism without compromising mTORC2‑dependent insulin signaling 1.
4. Tissue‑specific outcome – In γ2‑rich tissues, each AMPK pulse spikes nuclear FOXO3/PPARγ, activating autophagy (ULK1) and lipid‑oxidation genes; in γ1/γ3‑dominant tissues (e.g., subcutaneous adipocytes), weaker NUP50 modulation yields minimal transcriptional shift, explaining the AMPK expression‑activity disconnect observed in obesity 4.
5. Feedback and adaptation – Chronic AMPK activation leads to sustained NUP50 phosphorylation, causing compensatory up‑regulation of exportin‑1 and nucleoporin turnover, which dampens the import gate and triggers adaptation resistance—a testable prediction.

Experimental testability

• Phospho‑mutant NUP50: Generate knock‑in mice expressing NUP50 S→A (non‑phosphorylatable) or S→D (phosphomimetic). Predict that S→A abolishes AMPK‑pulse‑induced nuclear FOXO3/PPARγ accumulation and shortens healthspan benefits of intermittent fasting, whereas S→D mimics pulsed AMPK effects even under fed conditions.
• Isoform‑selective AMPK activator: Treat wild‑type and γ2‑knockdown mice with a γ2‑preferring compound (e.g., MK‑8722) in a 3‑day on/4‑day off regimen. Measure nuclear import of FOXO3/PPARγ, autophagy flux, and cardiac function. Expect enhanced benefits only in γ2‑intact hearts.
• Importin‑β1 inhibition: Use low‑dose ivermectin to transiently block importin‑β1 during AMPK pulses. Predict abrogation of lipid‑catabolism gene expression and loss of longevity advantage despite normal AMPK activation.
• Biomarker development: Quantify circulating phospho‑NUP50 levels in human subjects undergoing time‑restricted feeding; correlate with improvements in insulin sensitivity and lipid profiles.

If any of these experiments fail to show the predicted dependence of NUP50 phosphorylation on AMPK‑γ2 pulsatility and downstream transcriptional outcomes, the hypothesis is falsified.

References: 1, 2, 3, 4, 5.